Tremeau Pharmaceuticals focuses on orphan or unique disease states with a high unmet medical need for which there are no approved treatments.

Tremeau currently has two assets under development, outlined below.
 


TRM - 201 (Rofecoxib)

TRM - 201 (rofecoxib) is being developed for orphan and niche indications for which there is significant unmet medical need. The lead indication for TRM - 201 is Hemophilic Arthropathy (HA), a serious orphan disease for which high-potency opioids are the current standard of care.

Additional follow-on indications and formulations are under development.

Tremeau believes that the multiple, often industry-independent, scientific evaluations of the last 10 years strongly suggest a re-examination of the potential utility of Vioxx™, particularly in indications in which a COX-2 selective NSAID may provide therapeutic advantages over other standards of care, such as opioids.

Current Status:

TRM201 update.png

TRM - 359 (Etoricoxib)

TRM - 359 (etoricoxib) is being developed for the treatment of serious orphan and pediatric orphan diseases for which there are no approved therapies.

Tremeau believes that the multiple, often industry-independent, scientific evaluations of the last 10 years strongly suggest a re-examination of the potential utility of Arcoxia™, particularly in indications in which a COX-2 selective NSAID may provide therapeutic advantages over other standards of care.

Current Status:

TRM359 update.png
 

VIOXX and ARCOXIA are trademarks of Tremeau Pharmaceuticals, Inc.